Page 30 - Read Online

Connors. J Transl Genet Genom 2021;5:130-2 https://dx.doi.org/10.20517/jtgg.2021.17 Page 132

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
The author declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. King MC. "The race" to clone BRCA1. Science 2014;343:1462-5. DOI PubMed
2. Petrucelli N, Daly M, Feldman G. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med
2010;12:245-59. DOI PubMed
3. Suther S, Kiros GE. Barriers to the use of genetic testing: a study of racial and ethnic disparities. Genet Med 2009;11:655-62. DOI
PubMed
4. Childers KK, Maggard-Gibbons M, Macinko J, Childers CP. National Distribution of Cancer Genetic Testing in the United States:
Evidence for a Gender Disparity in Hereditary Breast and Ovarian Cancer. JAMA Oncol 2018;4:876-9. DOI PubMed PMC
5. National Comprehensive Cancer Network Guidelines (2020). Genetic/Familial High-Risk Assessment Breast and Ovarian, Retrieved
from https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf [Last accessed on 23 Mar 2021].
6. Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med
2016;375:443-53. DOI PubMed PMC
7. Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med 2015;373:1697-
708. DOI PubMed PMC
8. Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science 2017;355:1152-8. DOI PubMed PMC
9. CR, Lynch, HT. The history of Lynch syndrome. FAM CANCER 2013;12:145-57.
10. Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1
immunotherapy efficacy. J Hematol Oncol 2019;12:54. DOI PubMed PMC
11. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996;56:3087-
90. PubMed
12. Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer
cell lines. Int J Cancer 2003;106:66-73. DOI PubMed
13. Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology
1999;117:123-31. DOI PubMed PMC
14. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-6. PubMed